What's new

Orphan designation: Magrolimab Treatment of myelodysplastic syndromes, 26/06/2020 Withdrawn

Orphan designation: Magrolimab Treatment of myelodysplastic syndromes, 26/06/2020 Withdrawn

Mar 12, 2025 - 17:06
 0
Orphan designation: Magrolimab Treatment of myelodysplastic syndromes, 26/06/2020 Withdrawn
Orphan designation: Magrolimab Treatment of myelodysplastic syndromes, 26/06/2020 Withdrawn
Read More

Tags:

Previous Article

Orphan designation: Seladelpar Treatment of primary biliary cholangitis, 20/02/2...

Next Article

Orphan designation: Serplulimab Treatment of small cell lung cancer, 20/02/2025 ...

Related Posts

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Date of authorisation: 16/10/1998, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0

Clinical Trials Information System (CTIS) bitesize talk: End of transition period and notifications including serious breach, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 October 2024, 15:30 (CEST) to 16 October 2024, 17:00 (CEST)

Clinical Trials Information System (CTIS) bitesize talk...

Mar 3, 2025  0

European Shortages Monitoring Platform (ESMP) training on crisis and MSSG-led preparedness reporting for marketing authorisation holders (MAHs), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 19 February 2025, 10:00 (CET) to 19 February 2025, 12:30 (CET)

European Shortages Monitoring Platform (ESMP) training ...

Mar 13, 2025  0